Raloxifene Hcl
Rank #478 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$14.8M
Total Cost
198,063
Total Claims
$14.8M
Total Cost
7,407
Prescribers
$75
Cost per Claim
20,177
Beneficiaries
418,601
30-Day Fills
$1,993
Avg Cost/Provider
27
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$14.8M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $14.8M total
Top Prescribers of Raloxifene Hcl
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Yong Yu | Internal Medicine | Flushing, NY | 885 | $84K |
| 2 | Wei Lin | Internal Medicine | New York, NY | 1,357 | $82K |
| 3 | Henry Chen | Internal Medicine | Brooklyn, NY | 661 | $80K |
| 4 | Yin Win | Internal Medicine | New York, NY | 646 | $80K |
| 5 | Chang Lee | Internal Medicine | Flushing, NY | 1,216 | $78K |
| 6 | Bo Chen | Internal Medicine | New York, NY | 651 | $63K |
| 7 | Nora Tee | Family Practice | Alhambra, CA | 615 | $50K |
| 8 | Simon Chang | Obstetrics & Gynecology | Honolulu, HI | 252 | $46K |
| 9 | Tri-Dung Hoang | Internal Medicine | Sacramento, CA | 365 | $45K |
| 10 | Juliang Deng | Internal Medicine | Flushing, NY | 371 | $44K |
| 11 | Xiaoyuan Zhao | Internal Medicine | New York, NY | 417 | $44K |
| 12 | Benjamin Wu | Family Practice | Brooklyn, NY | 569 | $44K |
| 13 | James Wang | Family Practice | Los Angeles, CA | 653 | $42K |
| 14 | Jenny Cheng | Internal Medicine | New York, NY | 344 | $42K |
| 15 | Yiling Huang | Internal Medicine | Elmhurst, NY | 569 | $42K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 475 | Capmatinib Hydrochloride (Tabrecta) | $15.1M | 824 |
| 476 | Berotralstat Hydrochloride (Orladeyo) | $15.1M | 374 |
| 477 | Lansoprazole (Lansoprazole) | $15.0M | 309,355 |
| 478 | Raloxifene Hcl (Raloxifene Hcl) | $14.8M | 198,063 |
| 479 | Lanthanum Carbonate (Lanthanum Carbonate) | $14.7M | 13,783 |
| 480 | Mometasone Furoate (Mometasone Furoate) | $14.7M | 266,966 |
| 481 | Lorlatinib (Lorbrena) | $14.7M | 720 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology